Shuttle Pharmaceuticals Holdings, INC 10-Q quarterly reports

Shuttle Pharmaceuticals Holdings, Inc. reported a significant net loss for Q3 2025, faced termination of its primary CRO agreement, and secured new equity financing while expressing substantial doubt about its ability to continue as a going concern.

Shuttle Pharmaceuticals Holdings, Inc. reported a significantly wider net loss in Q2 2025, raising $8.9 million in net proceeds from equity financings but still facing substantial doubt about its ability to continue as a going concern.

Shuttle Pharmaceuticals Holdings, Inc. announces its financial results for the first quarter of 2025, showcasing a recent $5 million equity financing and ongoing clinical trial developments.

Shuttle Pharmaceuticals reported a net loss of $7.5 million for the nine months ended September 30, 2024, and faces substantial doubt about its ability to continue as a going concern despite recent capital raises.

Shuttle Pharmaceuticals reported a net loss of $3.8 million for the first half of 2024 and faces substantial doubt about its ability to continue as a going concern.

Shuttle Pharmaceuticals Holdings, Inc. has restated its financial statements for 2022 and 2023 due to accounting errors identified after its former auditor faced a cease-and-desist order from the SEC, and is now planning a capital raise to fund operations and clinical trials.

Shuttle Pharmaceuticals Holdings reported a net loss of $1.7 million for the first quarter of 2024 and is facing substantial doubt about its ability to continue as a going concern.